HK1223031A1 - 用於降低慢性肾病患者的心力衰竭的枸橼酸铁 - Google Patents

用於降低慢性肾病患者的心力衰竭的枸橼酸铁 Download PDF

Info

Publication number
HK1223031A1
HK1223031A1 HK16111332.6A HK16111332A HK1223031A1 HK 1223031 A1 HK1223031 A1 HK 1223031A1 HK 16111332 A HK16111332 A HK 16111332A HK 1223031 A1 HK1223031 A1 HK 1223031A1
Authority
HK
Hong Kong
Prior art keywords
increase
iron
reduce
kidney disease
chronic kidney
Prior art date
Application number
HK16111332.6A
Other languages
English (en)
Chinese (zh)
Inventor
恩裡克．普拉多蘇
恩里克．普拉多苏
羅恩．本圖爾
罗恩．本图尔
詹姆斯．
詹姆斯．F．奥利维耶罗三世
．奧利維耶羅三世
Original Assignee
凯克斯生物制药公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 凯克斯生物制药公司 filed Critical 凯克斯生物制药公司
Publication of HK1223031A1 publication Critical patent/HK1223031A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK16111332.6A 2013-11-04 2014-11-03 用於降低慢性肾病患者的心力衰竭的枸橼酸铁 HK1223031A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899866 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
HK1223031A1 true HK1223031A1 (zh) 2017-07-21

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111332.6A HK1223031A1 (zh) 2013-11-04 2014-11-03 用於降低慢性肾病患者的心力衰竭的枸橼酸铁

Country Status (15)

Country Link
US (3) US20160256486A1 (https=)
EP (2) EP3747432A1 (https=)
JP (3) JP2016535780A (https=)
KR (1) KR102392441B1 (https=)
CN (1) CN105873583A (https=)
AU (1) AU2014341975A1 (https=)
BR (1) BR112016009901A8 (https=)
CA (1) CA2928200A1 (https=)
EA (1) EA201690926A1 (https=)
HK (1) HK1223031A1 (https=)
IL (1) IL245317A0 (https=)
MX (1) MX2016005734A (https=)
SG (1) SG11201603091QA (https=)
TW (2) TWI744215B (https=)
WO (1) WO2015066593A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011011541A1 (en) 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
MX2021004640A (es) 2018-10-29 2021-05-28 Pharmacosmos Holding As Tratamiento de la deficiencia de hierro con carboximaltosa ferrica.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
EP4347022A1 (en) * 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (https=) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
CA2619591C (en) * 2005-08-18 2020-03-24 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
JP2009525277A (ja) * 2006-01-30 2009-07-09 グロボアジア エルエルシー 軟組織石灰化の回復、予防、遅延または安定化方法
WO2011011541A1 (en) * 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20130345303A1 (en) * 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
TW201609088A (zh) 2016-03-16
US20250360167A1 (en) 2025-11-27
TWI744215B (zh) 2021-11-01
CA2928200A1 (en) 2015-05-07
EP3065734A4 (en) 2017-05-17
SG11201603091QA (en) 2016-05-30
WO2015066593A1 (en) 2015-05-07
EP3747432A1 (en) 2020-12-09
AU2014341975A1 (en) 2016-05-19
JP2021073230A (ja) 2021-05-13
JP2016535780A (ja) 2016-11-17
EA201690926A1 (ru) 2016-09-30
KR20160096597A (ko) 2016-08-16
US20160256486A1 (en) 2016-09-08
EP3065734A1 (en) 2016-09-14
CN105873583A (zh) 2016-08-17
JP2019206562A (ja) 2019-12-05
IL245317A0 (en) 2016-06-30
US20190307791A1 (en) 2019-10-10
KR102392441B1 (ko) 2022-05-02
MX2016005734A (es) 2016-11-08
BR112016009901A8 (pt) 2020-04-14
JP6828100B2 (ja) 2021-02-10
TW202203910A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
WO2013192565A3 (en) Use of ferric citrate in the treatment of chronic kidney disease patients
HK1223031A1 (zh) 用於降低慢性肾病患者的心力衰竭的枸橼酸铁
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
MX2014011186A (es) Metodo para mejorar la eficiencia de las transfusiones de sangre.
WO2009125300A3 (en) Oxygenation procedures for newborns and devices for use therein
MX2015013170A (es) Proteinas de union especificas duales dirigidas contra tnf alpha.
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
WO2014089209A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
WO2014144280A8 (en) DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
Chavez et al. New insights into the regulation of vascular permeability
ES2543850R2 (es) Uso de complejos metálicos miméticos de SOD como agentes alimentarios y como cosméticos
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
PE20141577A1 (es) Espray para heridas
EA201500363A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
WO2011157819A3 (en) Peptides as active agents to stabilize biological barriers
MX2015001508A (es) El uso de antitrombina en la oxigenacion por membrana extracorporea.
WO2013142153A3 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
BR112014009414A2 (pt) uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos
JP2016511261A5 (https=)
NZ725920A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
PH12015501764A1 (en) Food composition and its use against dehydration
SG10201807066UA (en) Peptides and methods of use
MX2013013826A (es) Bebida para la reposicion rapida de iones calcio en el torrente sanguineo.